Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05146999 · ClinicalTrials.gov registry record · Phase 3
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 132
- Enrollment target
NCT05146999 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 132 participants.
The verdict
NCT05146999, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 132 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL QM1114-DP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2022-05-09 |
| Est. Completion | 2023-09-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05146999
The ClinicalTrials.gov registry entry for NCT05146999 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05146999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05146999 about?
NCT05146999 is a clinical study titled "Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines". The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines
What is the current status of trial NCT05146999?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 132 participants. The study started on 2022-05-09. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT05146999?
The interventions under investigation include: Placebo (BIOLOGICAL), QM1114-DP (BIOLOGICAL).
Who is sponsoring clinical trial NCT05146999?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.